Imunon, Inc. Q3 FY2024 earnings call

• Announced results from the large randomized Phase 2 study OVATION 2 in advanced ovarian cancer, showing an improvement in median overall survival of 11.1 months compared to the standard of care, with significant outcomes for patients not administered PARP inhibitors and those receiving at least 20% of IMNN-001 doses.
• Scientific Advisory Board recommends proceeding to a registrational Phase 3 trial with the dose studied in Phase 2.
• U.S. market opportunity for ovarian cancer with IMNN-001 exceeds $1.6 billion annually.
• Phase 1 proof-of-concept study for IMNN-001 as a seasonal COVID-19 booster vaccine is fully enrolled and on track to report data by end of 2024, with active BD activities for partnership.
• Strategic hires: Kristin Longobardi as Senior Vice President of Strategic Operations and Susan Eylward as General Counsel.
• Financials: Research and development expenses increased due to clinical spend related to OVATION 2 and the PlaCCin trial; general and administrative expenses decreased; net loss details for Q3 and year-to-date provided.

There is no detailed breakdown of product segments with revenue contributions provided in the transcript as the focus is on overall company performance and clinical studies rather than distinct product segments with specific revenue percentages.

• On track to begin Phase 3 registration trial in Q1 2025, expecting to enroll approximately 500 women with advanced ovarian cancer, with primary endpoint overall survival.
• Capital resources expected to fund operations into Q3 2025.
• Seasonal COVID-19 vaccine trial on track to report data before end of 2024, actively pursuing acquisition license or partnership for the asset.

• Regulatory uncertainties related to interactions with FDA and trial design approval.
• Financing risks depending on access to capital for Phase III and other studies.
• Data uncertainties as clinical study outcomes are not guaranteed.

Q: About Phase 3 study, percentage of advanced ovarian cancer patients on PARP inhibitors and combination treatments A: ~40% of patients in Phase 2 received PARP inhibitors, plan to balance HR deficiency group (BRCA mutation) in design; will discuss with FDA and include other treatments in protocol.

Q: Financing the study, plans for financing A: Cash runway includes launching the trial, looking for investor-friendly means to fully fund the study.

Q: Phase 3 meeting with FDA, trial design, partnership environment A: Expect to discuss Phase III proposal with FDA, protocol planned to be pulled together by end of year, Phase 1 data not yet available for partnership discussions.